# Update on the University of Calgary's Adoption and Implementation of ICH GCP E6 (R3)

Jenna Dobry-Dub Lead Regulatory Officer – Clinical Research Oct 27, 2025



## This presentation is not training for ICH GCP E6 (R3).



#### **Objectives**

- 1. General overview of the ICH GCP E6 (R3) guideline
- 2. Understand the anticipated timeline for adoption
- 3. Updates on available training and other tools
- Review the anticipated impact on Industry Sponsored & Investigator-Initiated trials



#### ICH GCP E6 (R3) guideline

#### Reorganization

- New section: Data Governance
- Protocol, Investigator Brochure and Essential Record Sections from R2 are now appendices in R3



#### ICH GCP E6 (R3) guideline

#### **Updated focus**

- Data Life Cycle
  - Electronic systems
  - Risk proportionality in data management
  - Blinding
- Risk proportionality
  - Quality by Design (QbD)
  - Critical to Quality Factors (CtQ)
- Responsibility
  - Added responsibilities to both sponsor & investigator



#### **Adoption Timeline**

- Health Canada is adopting the guideline E6 R3 on April 1, 2026.
- University of Calgary is "soft" adopting the guideline Jan 2026
  - Documents and tools will be updated per R3
  - Audits & monitoring conducted per R3 as of January in anticipation for April 1, 2026



#### **Training Requirements (IITs)**

- R2 to R3 Comparison Session conducted by N2 will be recognized as bridging training until R2 GCP certificate expires
  - Recording expires Dec 31, 2025
  - Self-attestation
- Optional CITI R3 GCP available today

 Industry sponsored trials – take direction from Sponsor



#### **Training**

- CITI R3 GCP update is available October 27 (today)
- N2 training sessions
  - Oct 1, 2025 & self attestation form available \*(bridging training)
- ICH E6(R3) training
  - Module 1 (Intro & Foundations) posted in October
  - Modules 2-5 coming soon
- Health Canada training sessions
  - Started hosting sessions in Fall & more coming
- Practical training during audits & monitoring
- Study-specific guidance available as needed



#### **Tools & Templates**

- Website & resource updates
  - Risk assessment & management
  - CtQ resources
  - Protocol deviation criteria
  - N2 resources updated soon
- N2 SOP V11 coming soon



#### **Industry Sponsored Trial Impact**

- Take direction from sponsor on training requirements
  - Investigators familiarize yourself with the updated responsibilities
- Request CtQs to be shared
- Monitoring should be risk-based and focussed on CtQs



#### **Investigator Initiated Trial Impact**

- CtQs will be required to be integrated into new protocol submitted to Health Canada
  - Health Canada has not yet commented on the requirement for currently active trials
  - ICH M11 protocol template
- Risk management plan (including CtQs)
- Multi-site
  - Sponsor responsibility to identify & share CtQs with subsites



### Questions?

jldobry@ucalgary.ca

